Cerebrospinal Fluid following Cerebral Ischemia Accelerates the Proliferation of Bone Marrow Stromal Cells in vitro

Orito, Kensuke; Harada, Hideki; Hara, Mitsuyoshi; Yamashita, Shine; Kikuchi, Kiyoshi; Shigemori, Minoru

doi:10.2739/kurumemedj.57.21

Cited by 4 publications

(2 citation statements)

References 32 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous grafts may have an additional advantage over allogenic grafts. In preclinical observations, MSCs reportedly developed function following contact with a conditioned media ( Egashira et al, 2013 ), serum ( Honmou et al, 2011 ), or cerebrospinal fluid from patients ( Orito et al, 2010 ), which is reflected in the biological responses to invasive stimulation. It is possible that MSCs may achieve proper function in reaction to insults ( Kurozumi et al, 2005 ; Xin et al, 2013 ).…”

Section: Controversies In Preclinical Stagementioning

confidence: 99%

Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

Ikegame

Yamashita

Nomura³

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are believed to be promising for cell administration therapy after ischemic stroke. Because of their advantageous characteristics, such as ability of differentiation into neurovascular lineages, avoidance of immunological problems, and abundance of graft cells in mesodermal tissues, studies regarding MSC therapy have increased recently. However, several controversies are yet to be resolved before a worldwide consensus regarding a standard protocol is obtained. In particular, the neuroprotective effects, the rate of cell migration to the lesion, and differentiation direction differ depending on preclinical observations. Analyses of these differences and application of recent developments in stem cell biology or engineering in imaging modality may contribute to identification of criteria for optimal stem cell therapy in which reliable protocols, which control cell quality and include safe administration procedures, are defined for each recovery phase after cerebral ischemia. In this mini review, we examine controversies regarding the fate of grafts and the prospects for advanced therapy that could be obtained through recent developments in stem cell research as direct conversion to neural cells.

show abstract

Section: Controversies In Preclinical Stagementioning

confidence: 99%

Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

Ikegame

Yamashita

Nomura³

et al. 2014

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Although immediately after the stroke there will be an increased permeability of the blood-brain barrier, permitting passive penetration of all kind of cells and trophic factors (Stamatovic, Keep et al 2008), the actual passage of stem cells is still limited (Jackson, Golding et al 2010). So, in the acute stage, intraarterial application of stem cells, and in the more chronic stage, the intrathecal administration of stem cells into the cerebrospinal fluid, flushing the brain, might give better results (Orito, Harada et al 2010). In chronic stages of stroke, neovascularization seems not to play a major role anymore.…”

Section: Ischemic Brain Injurymentioning

confidence: 99%

The patient's own bone marrow-derived stromal cells

Munter¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

70th Birthday symposium of Prof. Dr. Riederer: autologous adult stem cells in ischemic and traumatic CNS disorders

Munter¹,

Wolters

2012

J Neural Transm

View full text Add to dashboard Cite

Ischemic and traumatic insults of the central nervous system both result in definite chronic disability, only to some extent responsive to rehabilitation. Recently, the application of autologous stem cells (fresh bone marrow-derived mononuclear cells including mesenchymal and hematopoietic stem cells) was suggested to provide a strategy to further improve neurological recovery in these disorders. During the acute phase, stem cells act mainly by neuroprotection with prevention of apoptosis, whereas during the chronic situation they provide neurorestoration by transdifferentiation and/or the secretion of neurotrophic factors. To reach these goals, in the acute phase, stem cells (10 million mononuclear cells per kg body weight) might be best applied intravenously, as during the first 7 days after the lesion, the blood-brain barrier permits passage of cells from the blood into the brain or the spinal cord. In the more chronic situation, though, those cells might be applied best intrathecally by lumbar puncture. Based on the reported results so far, it seems justified to develop well-designed clinical double-blind trials in chronic spinal cord injury and ischemic stroke patients, as efficacy and safety concerns might not be answered by preclinical studies.

show abstract

Cerebrospinal Fluid following Cerebral Ischemia Accelerates the Proliferation of Bone Marrow Stromal Cells in vitro

Cited by 4 publications

References 32 publications

Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

Fate of graft cells: what should be clarified for development of mesenchymal stem cell therapy for ischemic stroke?

The patient's own bone marrow-derived stromal cells

70th Birthday symposium of Prof. Dr. Riederer: autologous adult stem cells in ischemic and traumatic CNS disorders

Contact Info

Product

Resources

About